Novartis MS drug cuts relapse rates by third in pivotal trials

Novartis reported that its investigational multiple sclerosis treatment reduced relapse rates by one-third compared to standard therapy in pivotal trials. The data, if confirmed, could reshape the MS treatment landscape and bolster Novartis's pipeline. Regulatory approval and market impact remain uncertain pending full data disclosure.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works